Ledger.Open graph →

SEC Form D · filed July 19, 2022

X4 Pharmaceuticals, Inc

Offering

$111.5M

Sold

$55.7M

Exemption

Rule 506(b)

Industry

Biotechnology

Location

BOSTON, MA

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (37)

Adam S. Mostafa · Boston, MAExec Alison E. Lawton · Boston, MADirector Gary J. Bridger · Boston, MADirector Mary S. Dibiase · Boston, MAExec Paula Ragan · Boston, MAExec · Director William E. Aliski · Boston, MADirector Michael S. Wyzga · Boston, MADirector David W. Mcgirr · Boston, MADirector Murray W. Stewart · Boston, MADirector Arthur S. Taveras · Boston, MAExec Francoise J. De Craecker · Boston, MADirector Benuel Esh · Atglen, PADirector Dustin Olson · Jacksonville, FLExec David Platt · Atglen, PADirector Kevin M. Swift · Corte Madera, CADirector Gary Zimmerman · Atglen, PADirector Todd Denton · Little Rock, ARDirector Thomas G. Hough · Warrendale, PAExec · Director Aaron Beiler · Atglen, PAExec David Finn · BOSTON, MADirector Brad Kalter · Jacksonville, FLExec Jacob Stoltzfus · Atglen, PADirector Diego S. Cadavid · Boston, MAExec Derek S. Meisner · Boston, MAExec Nan V. Shen · Woburn, MAExec Dhinakarraj Gantala · Palo Alto, CAExec Ahmed Alkhateeb · Palo Alto, CADirector Cormac Conroy · Palo Alto, CADirector Bruce Hallett · Palo Alto, CADirector Jeyanandh Paramesh · Palo Alto, CAExec · Director Pcmfm, LLC · Provo, UTExec Jason Danley · Provo, UTDirector Pmf Iii GP, LLC · Provo, UTDirector Chris Manning · Provo, UTDirector Jeff Danley · Provo, UTDirector Diego S. Cadavid · Boston, MAExec Derek S. Meisner · Boston, MAExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗